Theratechnologies Announces Financial Results for Third

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
106
Theratechnologies Announces Financial Results for Third Quarter of 2017

MONTREAL, QUEBEC--(Marketwired - Oct. 5, 2017) - Theratechnologies Inc. (Theratechnologies) (TSX:TH) today announced its financial results for the third quarter ended August 31, 2017.

Third quarter 2017 financial highlights

  • Net EGRIFTA ® sales reached $11,217,000
  • Adjusted EBITDA of $(2,046,000) 1
  • Liquidities of $29,578,000

"With three quarters into our fiscal year, our business plan is very much on track. Sales of EGRIFTA ® are growing and the ibalizumab file is progressing as we anticipated. In fact, we are even ahead of our plan for ibalizumab in Europe as we started investing in regulatory work much sooner than we expected," said Luc Tanguay, President and Chief Executive Officer, Theratechnologies inc.

1 See "Non-IFRS Financial Measures" below

"During our last quarter, EGRIFTA ® sales were up 26 percent compared to the same quarter last year, ibalizumab was accepted for filing and is currently being evaluated under priority review and the Food and Drug Administration ("FDA") gave a Prescription Drug User Fee Act ("PDUFA") target action date of January 3, 2018 for the ibalizumab application. While we are pleased with those accomplishments, we remain more than ever focused on making sure that we spare no effort to support the successful launch of ibalizumab," added Mr. Tanguay.

2017 Revised Guidance

We have adjusted our net sales revenue guidance to account for the recent strength of the CAD versus the USD and the possible impact of severe, adverse weather conditions on fourth quarter sales in Florida, Texas and Puerto Rico, which are three important EGRIFTA ® markets. Adjusted EBITDA will be affected by the anticipated lower net sales revenue as well as by higher ibalizumab expenses in Europe where more rapid than expected regulatory progress is being achieved. Net sales revenue of EGRIFTA ® for fiscal 2017 is now expected to be in the range of $42,000,000 to $44,000,000, compared to $44,000,000 to $46,000,000 in our previous report. Adjusted EBITDA for fiscal 2017 is now expected to be in the range of ($5,000,000) to ($5,500,000) compared to ($2,000,000) to ($3,000,000) in our previous report. See "Non-IFRS Financial Measures" below.

An assumed average exchange rate in the fourth quarter of USD 1 = CAD 1.22 was used in providing this guidance, compared to USD 1 = CAD 1.32 in our previous report.

Third Quarter Financial Results

The financial results presented in this press release are taken from the Company's Management's Discussion and Analysis, or MD&A, and unaudited consolidated financial statements for the period ended August 31, 2017, which have been prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB. The MD&A for the third quarter ended August 31, 2017 and the unaudited consolidated financial statements can be found at www.theratech.com and www.sedar.com . Unless specified otherwise, all amounts in this press release are in Canadian dollars and all capitalized terms have the meaning ascribed thereto in our MD&A. As used herein, EGRIFTA ® refers to tesamorelin for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. EGRIFTA ® is our registered trademark.

Consolidated revenue for the three- and nine-month periods ended August 31, 2017 was $11,217,000 and $30,268,000 compared to $8,925,000 and $26,695,000 in the comparable periods of fiscal 2016.

Revenue generated from net sales in the three- and nine-month periods ended August 31, 2017 was $11,217,000 and $30,266,000 compared to $8,924,000 and $26,691,000 in the comparable period of fiscal 2016. Revenue in 2017, for both the quarter and year-to-date, reflects increased unit volumes and higher prices compared to the comparable period in 2016, gains that were partially offset by changes in the mix of participating third-party payors as we move to expand our market to include more patients on Medicaid and other financial assistance programs. These programs typically involve rebates that reduce our average net selling price.

For the three- and nine-month periods ended August 31, 2017, cost of sales was $2,659,000 and $6,750,000 compared to $1,654,000 and $4,680,000 in the comparable period of fiscal 2016. Included in these amounts was cost of goods sold of $1,333,000 and $3,598,000, respectively, for the three- and nine-month periods ended August 31, 2017, compared to $1,005,000 and $3,007,000 in the comparable period of fiscal 2016. The increases in cost of goods sold were due to the higher sales in the 2017 periods.

Other production-related costs in the third quarter of fiscal 2017 amounted to $219,000, which was principally due to a write-down of inventory.

Finally, cost of sales in the three- and nine-month periods ended August 31, 2017 included royalties of $1,107,000 and $2,880,000, respectively compared to $659,000 and $1,673,000 in the comparable periods of fiscal 2016. Royalties became payable on EGRIFTA ® sales starting January 1, 2016 under the terms of an agreement with EMD Serono, Inc. The royalty percentage varies according to sales levels and the percentage being applied in fiscal 2017 is a blended rate based on expected sales for the year.

R&D expenses in the three- and nine-month periods ended August 31, 2017 amounted to $3,088,000 and $8,762,000 compared to $1,779,000 and $5,797,000 in the comparable periods of fiscal 2016.

The higher expenses in the 2017 periods include additional staff members in our medical science liaison and field medical education teams, whose role is to increase awareness about excess abdominal fat in HIV-infected patients with lipodystrophy and about MDR HIV-1. Other initiatives that led to higher costs in 2017 included: increased participation in symposiums, regulatory consulting for ibalizumab in Europe and development of the new F4 formulation of EGRIFTA ® .

R&D expenses also include costs associated with our two Phase 4 clinical trials, which amounted to $505,000 and $1,584,000 in the three- and nine-month periods ended August 31, 2017 compared to $709,000 and $2,031,000 in the comparable periods of fiscal 2016. Other components of R&D expenses include regulatory affairs and quality assurance activities.

Selling and Market Development expenses in the three- and nine-month periods ended August 31, 2017 amounted to $7,074,000 and $18,032,000 compared to $3,660,000 and $10,896,000 in the comparable periods of fiscal 2016. The year-over-year increase generally reflects the growth in our business and intensified marketing efforts.

The third quarter of 2017 included the full cost associated with the expansion of our U.S. sales team in order to cover additional territories and prepare for the potential launch of ibalizumab in the United States. We also added staff to our managed markets and reimbursement groups in 2017. Other projects that contributed to the year-over-year increase included the preparatory work on branded and unbranded ibalizumab campaigns and the development of a pricing strategy for ibalizumab in the United States.

Amortization of the intangible asset value established for the EGRIFTA ® commercialization rights amounted to $486,000 and $1,494,000 in the three- and nine-month periods ended August 31, 2017, compared to $490,000 and $1,506,000 in the prior-year periods.

General and Administrative expenses in the three- and nine-month periods ended August 31, 2017 amounted to $1,293,000 and $4,225,000, compared to $1,286,000 and $3,478,000 reported in the comparable periods of fiscal 2016. The increase in general and administrative expenses in 2017 is essentially attributable to the growth and development of the business.

Finance income , consisting of interest income, for the three- and nine-month periods ended August 31, 2017 was $95,000 and $244,000 compared to $21,000 and $80,000 in the comparable periods of fiscal 2016.

Finance costs for the three- and nine-month periods ended August 31, 2017 were $80,000 and $6,977,000 compared to a gain of $321,000 and costs of $1,687,000 in the comparable periods of fiscal 2016. These costs are almost entirely non-cash items. Finance costs in the third quarter of 2017 included a loss of $906,000 on financial instruments carried at fair value which was more than offset by a net foreign currency gain of $1,065,000. Finance costs for the nine-month period ended August 31, 2017 included a loss of $6,654,000 related to an increase in the fair value of outstanding warrants. Finance costs for the three- and nine-month periods ended August 31, 2017 also included $288,000 and $1,090,000, respectively, of accretion expense on our Long-term obligation, compared to $410,000 and $1,511,000 in the comparable periods of fiscal 2016.

Adjusted EBITDA for the three- and nine-month periods ended August 31, 2017 was ($2,046,000) and ($5,060,000) compared to $1,297,000 and $3,761,000 in the comparable periods of fiscal 2016. As noted above, a decrease in cash generated was planned and was principally due to the major expansion of our U.S. sales organization, added staffing in our medical science liaison and managed markets groups, as well as expenses related to ibalizumab in the United States and in Europe where more rapid than expected regulatory progress is being achieved. For a reconciliation of net loss and Adjusted EBITDA see "Non-IFRS Financial Measures" below.

Taking into account the revenue and expense variations described above, in particular, the investments made in organizational expansion and ibalizumab, we recorded a net loss of $2,882,000 or $0.04 per share in the three months ended August 31, 2017 compared to a net profit of $888,000 or $0.01 per share in the comparable period of fiscal 2016. In the nine-month period ended August 31, 2017 the net loss, which included a loss of $6,654,000 related to an increase in the fair value of outstanding warrants, was $14,234,000 or $0.20 per share compared to a net profit of $237,000 or nil per share in the comparable period of fiscal 2016.

As at August 31, 2017, cash, bonds, and money market funds amounted to $29,578,000 compared to $29,603,000 at May 31, 2017 and $11,603,000 at November 30, 2016.

Operating activities used $1,975,000 of cash in the three months ended August 31, 2017, compared to cash flows from operating activities of $513,000 in the comparable period of fiscal 2016. In the nine-month periods, cash flows from operating activities were $497,000 in 2017 compared to $3,000 in 2016.

In the third quarter of fiscal 2017, changes in operating assets and liabilities had a positive impact on cash flow of $598,000. These changes, which reflect the growth of our business and organizational expansion, included an increase in trade and other receivables of $1,191,000 and a $1,285,000 increase in accounts payable and accrued liabilities.

In the first nine months of fiscal 2017, changes in operating assets and liabilities positively affected cash flow by $6,359,000 compared to $3,656,000 of cash used in the comparable period of fiscal 2016. As was the case in the third quarter, the most significant changes were an increase in trade and other receivables of $2,447,000, and increased accounts payable and accrued liabilities of $7,577,000, reflecting the growth of our business and organizational expansion.

On December 5, 2016, the Company completed a public offering for the sale and issuance of 5,323,000 common shares for a gross cash consideration of $16,501,000. The Company also issued broker options for the sale and issuance of 212,920 common shares at an issue price of $3.10 per share, exercisable for a period of 18 months from the date of closing. The fair value of the broker options amounted to $183,000 and has been recorded in the share issue costs, which totaled $1,608,000.

In the three- and nine-month periods ended August 31, 2017, the Company received cash consideration of $2,582,000 and $7,900,000 respectively for the exercise of common share purchase warrants, broker options, broker warrants and stock options. Financing activities in both of the nine-month periods of fiscal 2017 and fiscal 2016 also included scheduled payments against the Long-term obligation of US$4,000,000 (C$5,390,000 in fiscal 2017 compared to C$5,196,000 in fiscal 2016).

Non-IFRS Financial Measures

Reconciliation of net profit or loss to adjusted earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA)

Adjusted EBITDA is a non-IFRS financial measure. A reconciliation of the Adjusted EBITDA to net profit (loss) is presented in the table below. We use adjusted financial measures to assess our operating performance. Securities regulations require that companies caution readers that earnings and other measures adjusted to a basis other than IFRS do not have standardized meanings and are unlikely to be comparable to similar measures used by other companies. Accordingly, they should not be considered in isolation. We use Adjusted EBITDA to measure operating performance from one period to the next without the variation caused by certain adjustments that could potentially distort the analysis of trends in our business, and because we believe it provides meaningful information on our financial condition and operating results.

We obtain our Adjusted EBITDA measurement by adding to net profit or loss, finance income and costs, depreciation and amortization, and income taxes. We also exclude the effects of certain non-monetary transactions recorded, such as share-based compensation for the stock option plan and write-downs of inventories, for our Adjusted EBITDA calculation. We believe it is useful to exclude these items as they are either non-cash expenses, items that cannot be influenced by management in the short term, or items that do not impact core operating performance. Excluding these items does not imply they are necessarily nonrecurring. Share-based compensation costs are a component of employee remuneration and can vary significantly with changes in the market price of the Company's shares. In addition, other items that do not impact core operating performance of the Company may vary significantly from one period to another. As such, Adjusted EBITDA provides improved continuity with respect to the comparison of our operating results over a period of time. Our method for calculating Adjusted EBITDA may differ from that used by other companies.

Reconciliation of non-IFRS financial information

(in thousands of Canadian dollars)

Three-month periods ended August 31, Nine-month periods ended August 31,
2017 2016 2017 2016
$ $ $ $
Net (loss) profit (2,882 ) 888 (14,234 ) 237
Add (deduct):
Depreciation and amortization 492 495 1,512 1,521
Finance costs 80 (321 ) 6,977 1,687
Finance income (95 ) (21 ) (244 ) (80 )
Share-based compensation for stock option plan 204 266 821 432
Write-down of inventories 155 (10 ) 108 (36 )
Adjusted EBITDA (2,046 ) 1,297 (5,060 ) 3,761

Conference Call Details

A conference call will be held today at 8:30 a.m. (ET) to discuss the results. The call will be hosted by Luc Tanguay, President and Chief Executive Officer. The conference call will be open to questions from financial analysts. Media and other interested individuals are invited to participate in the call on a "listen-only" basis.

The conference call can be accessed by dialling 1-877-223-4471 (North America) or 1-647-788-4922 (International). The conference call will also be accessible via webcast at http://www.gowebcasting.com/8852 . Audio replay of the conference call will be available until October 19, 2017, by dialling 1-800-585-8367 (North America) or 1-416-621-4642 (International) and by entering the playback code 84471075.

About Theratechnologies

Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs to promote healthy living and an improved quality of life among HIV patients. Further information about Theratechnologies is available on the Company's website at www.theratech.com and on SEDAR at www.sedar.com

Forward-Looking Information

This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management's beliefs and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as "may", "will", "should", "could", "would", "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the negatives of these terms, or variations of them. The forward-looking statements contained in this press release include, but are not limited to, statements regarding our anticipated revenue for EGRIFTA ® and adjusted EBITDA for the 2017 fiscal year, the approval of ibalizumab by the FDA and the launch of ibalizumab .

Forward-looking statements are based upon a number of assumptions and include, but are not limited to, the following: sales of EGRIFTA ® will continue to grow and we will meet our revised guidance on anticipated revenue of EGRIFTA ® and our anticipated Adjusted EBITDA for the 2017 fiscal year, the USD/CAD exchange rate will not vary during the remainder of the 2017 fiscal year, the FDA will not issue any order or decision negatively affecting the commercialization of EGRIFTA ® in the United States, the PDUFA target action date will be met, the FDA will approve ibalizumab, ibalizumab will be accepted by both patients and physicians (if approved) and our commercial infrastructure will be adequate to commercialize ibalizumab in the United States (if approved).

Forward-looking statements are subject to a variety of risks and uncertainties, many of which are beyond our control that could cause our actual results to differ materially from those that are disclosed in or implied by the forward-looking statements contained in this press release. Some of those risks include a decrease in sales of EGRIFTA ® during the 2017 fiscal year, a recall of EGRIFTA ® , the issuance of an order or decision by the FDA negatively affecting the commercialization of EGRIFTA ® , the non-approval of ibalizumab by the FDA and, even if approved, our incapacity to successfully launch ibalizumab.

We refer potential investors to the "Risk Factors" section of our Annual Information Form dated February 7, 2017 for additional risks and uncertainties regarding our business. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date.

We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.

Denis Boucher EXOCET Public Relations 514-913-1957
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 150

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 161

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 191

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 176

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 211

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 195

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 187

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 24

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 235

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading

Top 5 Most Recently Viewed Articles

Cameco Prepares for Leadership Transition at Westinghouse Electric

Updated Category News Views 149

Cameco Acknowledges Leadership Changes at Westinghouse Cameco (TSX: CCO; NYSE: CCJ) has made a significant acknowledgment regarding the leadership transition at Westinghouse Electric Company. This moment marks a pivotal change as Patrick Fragman announces his decision to step down from his role as President and CEO of Westinghouse. Effective March 31, 2025, Patrick will...

Continue Reading
Discover Innovations at Taiwan Innotech Expo 2025 in AI

Updated Category News Views 296

Taiwan Innotech Expo 2025 Highlights The Taiwan Innotech Expo (TIE) is set to showcase the critical role of artificial intelligence (AI) in transforming various industries. Hosted in Taipei, this annual event brings together influential government agencies, including the Ministry of Economic Affairs and the National Science and Technology Council. The expo will open its...

Continue Reading
Explore Antarctica: A Unique Journey with Atlas Ocean Voyages

Updated Category News Views 225

Unveiling a Unique Antarctic Adventure Atlas Ocean Voyages, known for its intimate luxury expeditions, is set to elevate its offerings with a remarkable new program on board the luxury ship, World Traveller. This journey promises to provide guests not only breathtaking landscapes but also enriching experiences through collaboration with renowned photographer Karim Iliya...

Continue Reading
atNorth's Bold Expansion: Norway Meets Mega Data Site

Updated Category News Views 48

Setting the Stage in Haugaland Here's a bold move from atNorth that's got folks talking. This Nordic heavyweight isn't just dancing around the edges; they're making a big splash by staking their claim in Norway with a mega site that’s got ‘future’ written all over it. We’re talking a data center in Haugaland, starting with 120MW and aiming for a solid 350MW once...

Continue Reading
Volvo Group's CES Keynote: Paving the Path to Sustainability

Updated Category News Views 192

Volvo Group Spearheads Sustainability at CES At CES, the Consumer Electronics Show, Volvo Group’s President and CEO, Martin Lundstedt, captured the audience with a strong call to action regarding the future of transportation and infrastructure. Lundstedt emphasized the dire need for urgent changes in the industry to combat climate change, setting the tone for a vibrant...

Continue Reading